Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
281 hedge funds and large institutions have $4.38B invested in Intra-Cellular Therapies Inc. in 2022 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 95 increasing their positions, 92 reducing their positions, and 36 closing their positions.
31% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 36
13% more capital invested
Capital invested by funds: $3.89B → $4.38B (+$495M)
3% more funds holding
Funds holding: 274 → 281 (+7)
3% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 92
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
20% less call options, than puts
Call options by funds: $16.9M | Put options by funds: $21M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$88.1M |
| 2 |
JP Morgan Chase
New York
|
+$65.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$23.9M |
| 4 |
BlackRock
New York
|
+$17.4M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$56.7M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$45M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$25.2M |
| 4 |
SC
Samlyn Capital
New York
|
-$25M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$23.1M |
ITCI Hedge Fund Activity: Q4 2022 in Review
281 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q4 2022, worth a combined $4.38B — up 13% from $3.89B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new ITCI positions and 36 closed out — a net gain of 11 holders — while 95 added to existing stakes and 92 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $88.1M. The largest seller was Lord, Abbett & Co, cutting an estimated $56.7M.
- 281 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q4 2022, up from 274 in Q3 2022.
- Funds reported $4.38B of Intra-Cellular Therapies Inc. stock for Q4 2022, up 13% quarter-over-quarter.
- 47 funds opened new Intra-Cellular Therapies Inc. positions in Q4 2022 and 36 closed out, a net change of +11 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q4 2022 was Fidelity Investments, an estimated $88.1M added.
- The largest Intra-Cellular Therapies Inc. seller in Q4 2022 was Lord, Abbett & Co, an estimated $56.7M sold.
Based on aggregated 13F filings for Q4 2022.